Aok 11 tender round: stada takes top active ingredients

Corporate News

AOK 11 tender round: STADA takes top active ingredients
Awards for omeprazole, risperidone, simvastatin and mirtazapine, among others
Bad Vilbel, February 5, 2013 – Following 18 awards in the tenth tender round of the Allgemeine Ortskrankenkasse (AOK) in the middle of January, Germany's largest association of statutory health insurance organizations has now once again selected STADA Group companies for six active ingredients in 38 alloted areas. In the process, STADA sales companies were awarded the four strongest active ingredients in terms of sales that were up for tender: omeprazole, risperidone, simvastatin and mirtazapine. These STADA products will now be available to the approximately 24 million individuals insured by “The tendered active ingredients that STADA won are among the most commonly needed medicines in existence”, says Hartmut Retzlaff, Chairman of the Executive Board of STADA Arzneimittel AG. “We are happy that we can make a significant contribution to the supply of medicine and therefore to people's health as the only independent generics Group in Germany. In consideration of the challenging conditions of the German discount agreement system, that does not go without saying.” The public health insurance association tendered a total of eight active ingredients each in eight alloted areas for three contract partners. STADApharm was awarded eight alloted areas for mirtazapine and omeprazole, five for risperidone, seven for simvastatin and one alloted area for the active ingredient combination of lisinopril and hydrochlorothiazide. ALIUD PHARMA was awarded eight areas for the active ingredient combination of losartan and hydrochlorothiazide as well as one alloted area for simvastatin. The contractual period STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA's business model focuses on the health care market. At the center of the internationally oriented business activities are the pharmaceutical and, in particular, the generics market with sustainable growth potentials. As a Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Axel Müller Chairman of the Supervisory Board: Dr. Martin Abend globally leading generics producer, STADA has a traditionally strong presence in Europe and is the clear number 3 in Germany. In financial year 2011, STADA achieved Group sales of EUR 1,715.4 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 337.2 million and adjusted net income of EUR 146.6 million. As of June 30, 2012, STADA employed 7,867 people worldwide. STADA Arzneimittel AG Corporate Communications D-61118 Bad Vilbel Tel.: +49(0) 6101 603-165 Fax: +49(0) 6101 603-506 e-mail: Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Axel Müller Chairman of the Supervisory Board: Dr. Martin Abend


Agitated patient

Management of Severe Agitation Key Points 1. The management of the severely agitated or violent patient embraces psychological, physical and pharmacological approaches. 2. Psychological methods focus on controlling the environment through the establishment of communication and trust. 3. Physical measures involve show of force and physical restraint. Physical restrain

Panasonic 080599

A Mitem View Customer Reference which would integrate with Panasonic’s Home Solution Overview Page and provide very high speed real timeaccess to the Vision System. Peter Schepis, Industry a wholly owned operating companyof Matsushita Electric Corporation ofGroup Manager of MIS commissioned a technol-Jersey. MECA is the North American arm ofogy team to identify and evaluate tools

Copyright 2014 Pdf Medic Finder